Evidence map›Paper›PMID 41162810›Full record

ArticleInternational journal of behavioral medicine2025

Effect of Prevalent and Incident Comorbidity Diagnoses on Quit Attempts and Prescription of Smoking Cessation Medications, HIV Outpatient Study, 2007-2022.

Li Jun, Carl Armon, Alexander Ewing, Jonathan Mahnken, Ellen Tedaldi, Frank Palella, Richard M Novak, Cynthia Firnhaber, Stockton Mayer, Andrea Wendrow and 4 more

Abstract read
In one paragraph

Article in International journal of behavioral medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Li JunDivision of HIV Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA. FFA2@cdc.gov.
Carl ArmonCerner Corporation, Kansas City, MO, USA.
Alexander EwingDivision of HIV Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Jonathan MahnkenKansas University Medical Center, Kansas City, MO, USA.
Ellen TedaldiLewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
Frank PalellaNorthwestern University Feinberg School of Medicine, Chicago, Illinios, USA.
Richard M NovakUniversity of Illinois College of Medicine, Chicago, IL, USA.
Cynthia FirnhaberVivent Health, Denver, CO, USA.
Stockton MayerUniversity of Illinois College of Medicine, Chicago, IL, USA.
Andrea WendrowUniversity of Illinois College of Medicine, Chicago, IL, USA.
Gina SimonciniAIDS Healthcare Foundation, Philadelphia, PA, USA.
Linda BattaloraAIDS Healthcare Foundation, Philadelphia, PA, USA.
Kate BuchaczDivision of HIV Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
HIV Outpatient Study (HOPS) Investigators

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundPeople with HIV (PWH) are more likely to smoke, have comorbidities, and be less likely to quit than the general population. This study aimed to describe the prescription of smoking cessation medications and quit smoking attempts, and to assess the effect of prevalent and incident comorbidity diagnoses on these two outcomes.

methodsWe analyzed the 2007-2022 HIV Outpatient Study (HOPS) medical records and self-reported risk behavior survey data. We included adult PWH with evidence of current cigarette use at enrollment (baseline) or incident cigarette use. Comorbidities were identified based on laboratory results, clinical diagnoses, and treatments. We assessed associations of time-updated (baseline and incident) comorbidity diagnosis with prescription of smoking cessation medications and first attempt to quit using Cox proportional hazards analyses.

resultsAmong 1068 eligible participants followed over a median time of 3.1 years (interquartile range 1.2-6.8 years), 304 (29%) were prescribed smoking cessation medications. Multivariable factors positively associated with prescribed smoking cessation medications included year of first HOPS visit (adjusted hazard ratio (aHR) 1.09), having diagnoses of depression (aHR 1.39), or chronic obstructive pulmonary disease/emphysema (aHR 1.89). Among 464 people who smoked at baseline and had at least one ACASI survey, during a median follow-up time of 2.3 years (interquartile range 0.8-5.2 years), 163 (35%) attempted to quit smoking. Multivariable factors positively associated with first attempt to quit included year of first HOPS visit (aHR 1.24), having a diagnosis of depression (aHR 1.30) or bipolar disorder (aHR 1.62), and being prescribed smoking cessation medications (range aHR 2.62-aHR 5.97, depending on the medication), whereas having a diagnosis of psychosis (aHR 0.29), hypertension (aHR 0.41), or obesity (aHR 0.49) was inversely associated.

conclusionIn the HOPS, about one-third of smokers were prescribed smoking cessation medications, and of those who completed the risk behavior survey, one-third attempted to quit. Among incident comorbidities examined, time-updated depression was both positively associated with being prescribed smoking cessation medications and attempting to quit smoking. Our results highlight the need for better integration of smoking cessation and prevention programs into PWH care.

Indexed as

ComorbidityHIV infectionsSmokersSmoking cessation

Identifiers

PMID41162810
PMCPMC12706768

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.